Atossa Therapeutics – Consensus Indicates Potential 468.2% Upside

Broker Ratings

Atossa Therapeutics with ticker code (ATOS) have now 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 7.5 and 5 calculating the average target price we see 6.25. Now with the previous closing price of 1.1 this would indicate that there is a potential upside of 468.2%. The day 50 moving average is 1.12 and the 200 moving average now moves to 2.32. The company has a market cap of $46m. Find out more information at:

Atossa Therapeutics develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company’s lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics in January 2020. Atossa Therapeutics was founded in 2009 and is headquartered in Seattle, Washington.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index